secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091353
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports Q3 net loss $20.7M; reiterates Aug 29 PDUFA for ONS-5010
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders of $20.7M ($0.08/share) vs $17.5M in prior-year quarter.
- Cash and cash equivalents of $33.7M expected to fund operations through potential BLA approval in Q3 2023.
- FDA PDUFA goal date of August 29, 2023 for ONS-5010 (ophthalmic bevacizumab) for wet AMD.
- Pre-launch activities ongoing with AmerisourceBergen distribution partnership for U.S. launch.
- MAA decision from EMA CHMP for ONS-5010 in EU expected in first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/0001104659-23-091353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923091353/tm2323752d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer